X0306 4 2021-09-09 0 0001326110 ImmunityBio, Inc. IBRX 0001848899 Sachs David C. C/O IMMUNITYBIO, INC. 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer Common Stock 2021-09-09 4 M 0 7598 0.00 A 26458 D Restricted Stock Units 2021-09-09 4 M 0 7598 0.00 D Common Stock 7598 161633 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. 17,242 of the restricted stock units ("RSUs") will vest on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the Units (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining Units will vest on December 31, 2026. Exhibit 24 - Power of Attorney /s/ Steven Yang, as Attorney-in-Fact 2021-09-13